Table 2 The distributions of demographic and clinicophathological characteristics according to tertile of lipocalin-2 and MMP-9 in all patients
| Â | Lipocalin-2 (ng/ml) | MMP-9 (ng/ml) | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | t1 | t2 | t3 | Â | Â | Â | Â | P trend a |
| Â | (2.63-59.03) | (59.03-109.65) | (109.65-772.34) | Â | (0.15-34.42) | (34.42-80.36) | (80.36-397.09) | |
Age, mean (SD) | 46.5 (11.6) | 47.3 (10.6) | 45.9 (9.9) | 0.67b | 48.2 (10.5) | 44.4 (9.8) | 47.1 (11.5) | 0.58b |
Premenopausal status, % | 65.0 | 60.4 | 64.4 | 0.93 | 53.0 | 72.6 | 64.0 | 0.11 |
BMI < 25 kg/m2, % | 82.0 | 74.5 | 70.3 | 0.05 | 77.0 | 78.4 | 71.3 | 0.35 |
TNM stage, % | ||||||||
  I | 32.0 | 40.2 | 41.6 | 0.59 | 35.0 | 46.1 | 32.7 | 0.72 |
  IIA –IIB | 48.0 | 39.2 | 34.7 |  | 39.0 | 35.3 | 47.5 |  |
  IIIA –IIIC | 20.0 | 20.6 | 23.8 |  | 26.0 | 18.6 | 19.8 |  |
Tumor size < 2cm, % | 46.0 | 53.9 | 57.4 | 0.11 | 47.0 | 62.8 | 47.5 | 0.95 |
Lymph-node negative, % | 57.0 | 54.9 | 56.4 | 0.94 | 55.0 | 60.8 | 52.5 | 0.72 |
Histologic grade I-II, % | 48.9 | 61.2 | 55.7 | 0.36 | 48.4 | 62.2 | 55.2 | 0.35 |
Nuclear grade I-II, % | 51.6 | 58.0 | 54.1 | 0.73 | 52.1 | 57.0 | 54.6 | 0.72 |
ER positive, % | 56.0 | 59.8 | 55.5 | 0.94 | 53.0 | 61.8 | 56.4 | 0.63 |
PR positive, % | 51.0 | 54.9 | 51.5 | 0.95 | 48.0 | 58.8 | 50.5 | 0.73 |
Adjuvant chemotherapy Yes, % | 75.8 | 66.7 | 75.8 | 0.99 | 74.2 | 70.0 | 74.0 | 0.98 |
Radiation therapy Yes, % | 62.2 | 58.0 | 65.0 | 0.69 | 67.7 | 60.6 | 57.0 | 0.12 |
Hormone receptor therapy Yes, % | 63.6 | 69.0 | 66.0 | 0.73 | 62.6 | 70.0 | 66.0 | 0.61 |